Please note that following on from information provided to NICE by the company in May 2020, the appraisal of ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1025

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
24 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in May 2020, the appraisal of ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
22 May 2020 Suspended. Topic has been suspended
02 February 2018 In progress. In progress

For further information on our processes and methods, please see our CHTE processes and methods manual